612. Acute Lymphoblastic Leukemia: Clinical Studies: Innovative Chemotherapy and Immunotherapy Strategies in Frontline and Relapsed Disease
Watch Session
266 Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children’s Oncology Group (COG) Trial AALL1231 according to ASH clinically relevant abstract
David T. Teachey, Meenakshi Devidas, Brent L Wood, et al
Matthias Stelljes, Simon Raffel, Ralph Wäsch, et al.
268 Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial according to ASH clinically relevant abstract
Franco Locatelli, Gerhard Zugmaier, Carmelo Rizzari, et al.
269 Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival according to ASH clinically relevant abstract
Agne Taraseviciute, Seth M. Steinberg, Regina M. Myers, et al
Xian Zhang, Jiasheng Wang, Yue Liu, et al
Giacomo Gotti, Maneka Puligandla, Kristen E. Stevenson, et al